In addition to today’s resource, please review Amyloid‐beta‐targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Cochrane Database Syst Rev. 2026 Apr 16;4(4):CD016297. doi: 10.1002/14651858.CD016297.
Authors’ conclusions: The effect of amyloid-beta-targeting monoclonal antibodies on cognitive function and dementia severity at 18 months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease is trivial, while on functional ability, it is small at best. Amyloid-beta-targeting monoclonal antibodies increase the risk of amyloid-related imaging abnormalities. Both desirable outcomes and adverse events were inconsistently reported in the studies included in the review. Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Future research on disease-modifying treatments for Alzheimer’s disease should focus on other mechanisms of action.
Today, I review, link to, and excerpt from Beyond the Cochrane review: Re-evaluating anti-amyloid therapy in Alzheimer’s disease [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Alzheimers Dement. 2026 Aug;22(8):e71769. doi: 10.1002/alz.71769.
All that follows is from the above resource.
- Abstract
- Highlights
- 1. INTRODUCTION
- 2. METHODOLOGICAL CONSIDERATIONS
- 3. ACCESSIBILITY AND FEASIBILITY BARRIERS TO ALZHEIMER’S AMYLOID‐TARGETING THERAPIES
- 4. ANTI‐AMYLOID THERAPY SAFETY PROFILE
- 5. COGNITIVE OUTCOMES AND CLINICAL IMPLICATIONS OF AATs
- 6. SYNERGISTIC MULTI‐MECHANISM PATHWAY INVESTIGATION WITH AATs
- 7. CONCLUSION
- CONFLICT OF INTEREST STATEMENT
- Supporting information
- ACKNOWLEDGMENT
- REFERENCES
- Associated Data
Abstract
The global burden of Alzheimer’s disease (AD) is accelerating, with U.S. prevalence projected to reach nearly 13 million by 2060. Although the “amyloid cascade hypothesis” has long-guided drug development, a 2026 Cochrane review challenged amyloid beta (Aβ) targets for therapy by citing insufficient clinical benefit and safety concerns. We highlight several methodological limitations in this study. The primary concern is a “dilution effect” caused by analyzing monomer-selective antibodies alongside newer treatments that directly target toxic Aβ plaques. This statistical noise, compounded by a decade of failed studies, obscures the significant cognitive preservation achieved by U.S. Food and Drug Administration (FDA)-approved therapies, like lecanemab and donanemab. We contend that these cognitive outcomes are clinically meaningful, as dismissing them ignores the vital impact on preserved independence and reduced caregiver burden. We emphasize current stratified safety frameworks for amyloid-related imaging abnormalities (ARIA) management. The path forward lies in an integrated framework combining Aβ clearance with novel, multi-pathway therapies.
Keywords: Alzheimer’s disease; Cochrane review; amyloid beta; amyloid cascade hypothesis; amyloid‐related imaging abnormalities (ARIA); anti‐amyloid therapy; cognition; donanemab; lecanemab.
© 2026 The Author(s). Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
